{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-25-005124","form_type":"8-K","ticker":"APTOF","cik":"0000882361","company_name":"Aptose Biosciences Inc.","filed_at":"2025-08-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:46.568287+00:00","generated_at":"2026-05-17T20:16:42.846055+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Aptose TUSCANY trial advances to 160 mg TUS dose; receives additional $1.1M loan from Hanmi","bullets":["CSRC approved escalation to 160 mg TUS dose after no dose-limiting toxicities at 40, 80, and 120 mg cohorts.","TUS+VEN+AZA triplet achieved CRs and MRD negativity in patients with adverse TP53 and FLT3-ITD mutations.","Aptose received $1.1M advance from Hanmi under $8.5M loan, bringing total advances to $5.6M.","Enrollment open for 160 mg cohort; all 120 mg patients remain on study.","Trial anticipates enrolling 18-24 patients by late 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-25-005124","json":"https://secwatch.observer/filing/0001171843-25-005124.json","markdown":"https://secwatch.observer/filing/0001171843-25-005124.md","text":"https://secwatch.observer/filing/0001171843-25-005124.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/882361/000117184325005124/0001171843-25-005124-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/882361/000117184325005124/f8k_080625.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T20:16:42.846055+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}